For more information or to REGISTER: CLICK HERE – or if member ➡️

COME HOME Treatment Pathways - Index

Evidence Based, Physician Driven, Open Source

COME HOME treatment pathways are developed and maintained by committees of community and academic oncologists. They are a freely available open source tool. Pathway committees meet twice monthly during new pathway development, and then quarterly to update the pathways and keep them current. Links are provided for comprehensive NCCN documentation (NCCN login required). These pathways were formerly displayed on the Innovative Oncology Business Solutions (IOBS) website, but are now a project of the National Cancer Care Alliance. Extensive updates to the formatting are underway as each pathway is reviewed, with improved style and content.

Click Cancer Type, or a specific Stage. Additional stage navigation in footer thumbnails on each page.
Cancer Type Stage Updated NCCN
Bladder Cancer NCCN
Breast Cancer DCIS
Stage I-III
Recurrent or Stage IV: ER or PR pos
Recurrent or Stage IV ER/PR neg or endocrine refractory
2018 . 02 . 09 NCCN

Colon Cancer
(Rectal Cancer: See below)

Stage II
Stage III
Stage IV PS 0-2
Stage IV PS 3-4
2017 . 07 . 28 NCCN
Hodgkin Lymphoma Stage IA or IIA Favorable
Stage I-II Unfavorable
Stage III-IV
Refractory Disease
2018 . 03 . 02 NCCN
Kidney (Renal) Cancer NCCN
Melanoma Stage 0-IA
Resectable Stage IB or II
Resectable Stage III
Stage III or In-Transit
Unresectable Stage III-IV Good PS (0-2)
Unresectable Stage III-IV Poor PS (3-4)
2018 . 01 . 12 NCCN
Non-Hodgkin B-Cell Lymphomas NCCN
Non-Small Cell Lung Cancer (NSCLC) Stage IA
Stage IB, IIA, IIB
Stage IIIA
Stage IIIB
Metastatic Dis 1st line Rx Non-Squamous
Metastatic Dis 1st line Rx Squamous
Metastatic Dis 2nd line Rx
2018 . 02 . 16
(Pending approval)
NCCN
Pancreatic Cancer Neoadjuvant
Adjuvant
Locally Advanced
Metastatic or Recurrent
2018 . 02 . 23
(Pending approval)
NCCN
Prostate Cancer NCCN
Rectal Cancer NCCN
Thyroid Cancer Metastatic Follicular, Hurthle Cell, Papillary
Anaplastic
Medullary
2018 . 03. 09 NCCN